No difference in delayed hypersensitivity between breast and cervical carcinomas.
DNCB and PPD skin testing was performed in 130 breast and 110 cervical cancer patients. BATES' instruction with a plea for uniformity was used [1]. Patients were tested while being diagnosed and prior to the treatment. No significant differences either in the frequency of a reactivity or grade of response in corresponding stages of breast and cervical cancer were found.
D001943:Breast Neoplasms / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology*; D007111:Immunity, Cellular; D008875:Middle Aged; D009367:Neoplasm Staging; D012882:Skin Tests; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology